🚀 VC round data is live in beta, check it out!
Cosmo Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cosmo Pharmaceuticals and similar public comparables like Avadel Pharmaceuticals, Sarepta Therapeutics, Bausch Health, Hepalink and more.
Cosmo Pharmaceuticals Overview
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Founded
1997
HQ
Employees
322
Website
Financials (LTM)
EV
$2B
Cosmo Pharmaceuticals Financials
Cosmo Pharmaceuticals reported last 12-month revenue of $127M and EBITDA of $18M.
In the same LTM period, Cosmo Pharmaceuticals generated $64M in gross profit, $18M in EBITDA, and $1M in net income.
Cosmo Pharmaceuticals P&L
In the most recent fiscal year, Cosmo Pharmaceuticals reported revenue of — and net income of —.
Cosmo Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $127M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $64M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | — | XXX | XXX | XXX |
| EBITDA | $18M | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | — | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | — | XXX | XXX | XXX |
| Net Profit | $1M | XXX | — | XXX | XXX | XXX |
| Net Margin | 1% | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cosmo Pharmaceuticals Stock Performance
Cosmo Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Cosmo Pharmaceuticals' stock price is $123.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCosmo Pharmaceuticals Valuation Multiples
Cosmo Pharmaceuticals trades at 15.6x EV/Revenue multiple, and 111.7x EV/EBITDA.
Cosmo Pharmaceuticals Financial Valuation Multiples
As of April 25, 2026, Cosmo Pharmaceuticals has market cap of $2B and EV of $2B.
Equity research analysts estimate Cosmo Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cosmo Pharmaceuticals has a P/E ratio of 2059.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 15.6x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | 111.7x | XXX | — | XXX | XXX | XXX |
| EV/EBIT | 1171.2x | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 30.8x | XXX | — | XXX | XXX | XXX |
| P/E | 2059.4x | XXX | — | XXX | XXX | XXX |
| EV/FCF | 168.8x | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cosmo Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cosmo Pharmaceuticals Margins & Growth Rates
Cosmo Pharmaceuticals' revenue in the last 12 month grew by 15%.
Cosmo Pharmaceuticals' rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cosmo Pharmaceuticals' rule of X is 62% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cosmo Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 172% | XXX | — | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 62% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 26% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 31% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cosmo Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cosmo Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Avadel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarepta Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bausch Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Hepalink | XXX | XXX | XXX | XXX | XXX | XXX |
| Zymeworks | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cosmo Pharmaceuticals M&A Activity
Cosmo Pharmaceuticals acquired XXX companies to date.
Last acquisition by Cosmo Pharmaceuticals was on XXXXXXXX, XXXXX. Cosmo Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cosmo Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCosmo Pharmaceuticals Investment Activity
Cosmo Pharmaceuticals invested in XXX companies to date.
Cosmo Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Cosmo Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cosmo Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cosmo Pharmaceuticals
| When was Cosmo Pharmaceuticals founded? | Cosmo Pharmaceuticals was founded in 1997. |
| Where is Cosmo Pharmaceuticals headquartered? | Cosmo Pharmaceuticals is headquartered in Switzerland. |
| How many employees does Cosmo Pharmaceuticals have? | As of today, Cosmo Pharmaceuticals has over 322 employees. |
| Who is the CEO of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' CEO is Giovanni Di Napoli. |
| Is Cosmo Pharmaceuticals publicly listed? | Yes, Cosmo Pharmaceuticals is a public company listed on Berlin Stock Exchange. |
| What is the stock symbol of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals trades under C43 ticker. |
| When did Cosmo Pharmaceuticals go public? | Cosmo Pharmaceuticals went public in 2007. |
| Who are competitors of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals main competitors are Avadel Pharmaceuticals, Sarepta Therapeutics, Bausch Health, Hepalink. |
| What is the current market cap of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' last 12 months revenue is $127M. |
| What is the current revenue growth of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Cosmo Pharmaceuticals? | Current revenue multiple of Cosmo Pharmaceuticals is 15.6x. |
| Is Cosmo Pharmaceuticals profitable? | Yes, Cosmo Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' last 12 months EBITDA is $18M. |
| What is Cosmo Pharmaceuticals' EBITDA margin? | Cosmo Pharmaceuticals' last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Cosmo Pharmaceuticals? | Current EBITDA multiple of Cosmo Pharmaceuticals is 111.7x. |
| What is the current FCF of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals' last 12 months FCF is $12M. |
| What is Cosmo Pharmaceuticals' FCF margin? | Cosmo Pharmaceuticals' last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Cosmo Pharmaceuticals? | Current FCF multiple of Cosmo Pharmaceuticals is 168.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.